Pipeline

February 2, 2020

Company	Drug/Device	Medical Condition	Status
ORIC Pharmaceuticals	ORIC-101 in combination with XTANDI (enzalutamide)	metastic prostate cancer	phase 1b trial dosing first patient
Syros Pharmaceuticals	SY-5609	select solid tumors	phase 1 trial dosing first patient
Ikena Oncology	IK-175 (formerly KYN-175)	advanced solid tumors	phase 1 trial dosing first patient
Rubius Therapeutics	RTX-134	phenylketonuria	phase 1b trial dosing first patient
Cerevel Therapeutics	CVL-936	substance use disorder	phase 1 trial initiated
GlycoMimetics	GMI-1359	advanced breast cancer	phase 1b trial dosing first patient
Epygenix Therapeutics	EPX-100	Dravet Syndrome	phase 1 trial completed
Hansa Biopharma	imlifidase	Anti-GBM antibody disease	phase 2 investigator-initiated trial enrolling 15 patients
Anavex Life Sciences	ANAVEX 2-73 (blarcamesine)	Parkinson’s Disease	phase 2 trial enrolling 120 patients at 20 sites across Spain and three sites in Australia
Cassava Sciences	PTI-125	Alzheimer’s Disease	phase 2b trial enrolling 64 patients
Isofol Medical	arfolitixorin	metastatic colorectal cancer	phase 1/2 trial completed
VistaGen Therapeutics	AV-101 oral NMDAR (N-methyl-D-aspartate receptor)	dyskinesia in patients with Parkinson's Disease receiving levodopa-based therapy	phase 2 IND cleared by the FDA
NuCana	Acelarin (NUC-1031)	biliary tract cancer	phase 3 trial dosing first patients in U.S. and Europe
Abbott	Infinity Deep Brain Stimulation system	Parkinson’s Disease	approved by the FDA for new indication
Epizyme	Tezverik (tazemetostat)	metastatic or locally advanced epithelioid sarcoma not eligible for complete resection	approved by the FDA
Merck	Dificid (fidaxomicin)	Clostridioides difficile-associated diarrhea in children ages six months and older	approved by the FDA
Teva Pharmaceuticals USA	AJOVY (fremanezumab-vfrm) autoinjector	migraine	approved by the FDA
Boehringer Ingelheim Eli Lilly	Trijardy XR	type 2 diabetes	approved by the FDA
Pharmacosmos Therapeutics	Monoferric (ferric derisomaltose) injection	iron deficiency anemia	approved by the FDA